Immune Checkpoint and BRAF/MEK Inhibitor- directed Therapies for Advanced Melanoma – Live

Description

Program Description

---

Click to Go to the Event Registration

Treatment options for advanced-stage melanoma have improved dramatically with the introduction of immune checkpoint inhibitors and BRAF and MEK inhibitors. Blocking programmed death 1 (PD-1) in melanoma may enhance the durability of anti-tumor responses induced by the combined inhibition of BRAF and MEK. The presence of shared epitopes (e.g., troponin, desmin, and myosin) between melanoma cells and myocardium is proposed as the primary mechanism of ICI-induced myocarditis. In contrast to ICI-related cardiac irAEs, BRAFi/MEKi mediated cardiac adverse events are due to the critical role of the Ras-Raf-MEK-ERK signaling in the survival of cardiomyocytes. With the emerging application of ICI-BRAFi/MEKi combinations, differentiating between these two types of cardiotoxicities will become essential for appropriate patient management.

Agenda

---

• Clinical Vignette 1 (Pretest – Audiences Response System)
• The immune checkpoint inhibitor (ICI) and BRAF/MEK targeted agent-based treatment of melanoma
• Clinical Vignette 1 (Posttest – Audiences Response System)
• Clinical Vignette 2 (Pretest – Audiences Response System)
• Management of immune-related adverse events associated with targeted therapy and ICI combinations in patients with melanoma
• Clinical Vignette 2 (Post-test Audiences Response System)
• Questions from the audience and Panel Discussion

Intended Audience

---

Oncologists, nurse practitioners, physician assistants, and nurses.

Commercial Supporter

---

Supported by an educational grant from Merck Sharp & Dohme